Harmony Biosciences investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) securities.
On March 28, 2023, before the market opened, market analyst Scorpion Capital published a report on Harmony Biosciences. The report alleged, among other things, that Harmony Biosciences’ drug, Wakix, is unsafe and causes heart-related issues, including sudden cardiac death, to occur in otherwise healthy patients. Additionally, the report indicated that “explosive information was concealed from the FDA that would have prevented approval” of Wakix by the regulators. The report further alleged that Wakix has “alarming toxicity,” “no efficacy,” is based on “sham patents,” and “scam clinical trials,” and has been “pushed via false advertising and a vast off-label and physician kickback scheme.”
Following this news, Harmony Biosciences’ stock price fell $10.70 per share, or 25.8%, to close at $30.80 per share on March 28, 2023.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at firstname.lastname@example.org.